EvidentlQ Germany
EvidentlQ Germany is recorded as a service provider in 12 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 12 of 12 trials · Latest update first
SGLT2 INHIBITION FOR CARDIOVASCULAR ENDPOINT REDUCTION IN HYPERTENSION (SGLT2-HYPE)
Sponsor Universitaetsklinikum Schleswig-Holstein AöR
- Start (EU)
- Latest update
- Estimated end
Effects of ziltivekimab versus placebo on coronary atherosclerosis in patients with acute myocardial infarction. A serial, multivessel, intravascular ultrasound, near-infrared spectroscopy and optical coherence tomography imaging study
Sponsor Novo Nordisk A/S
- Start (EU)
- Latest update
- Estimated end
A single-arm, multi-center, open-label Phase II study to determine the safety and efficacy of MB-CART2019.1 in pediatric subjects with relapsed/refractory (r/r) mature B-cell neoplasms who have relapsed after one or more prior therapies, including subjects with primary refractory disease
Sponsor Miltenyi Biomedicine GmbH
- Start (EU)
- Latest update
- Estimated end
- Not reported
A double-blind, randomized, placebo-controlled, two arm, phase II clinical trial in parallel groups to evaluate the efficacy and tolerability of a rectal treatment with budesonide suppositories compared to placebo suppositories for amelioration of acute radiation proctitis symptoms in male patients aged 18 years or older with prostate carcinoma
Sponsor Dr. Falk Pharma GmbH
- Start (EU)
- Latest update
- Estimated end
A multi-center single arm Phase II study to evaluate the safety and efficacy of genetically engineered autologous cells expressing anti-CD20 and anti-CD19 specific chimeric antigen receptor in subjects with relapsed and/or refractory diffuse large B cell lymphoma
Sponsor Miltenyi Biomedicine GmbH
- Start (EU)
- Not reported
- Latest update
- Estimated end
A Phase 2b, Multicenter, Randomized, Placebo-controlled, Double-blind Study to Assess the Safety and Efficacy of AD04 in Patients with Early Alzheimer’s Disease - ADVANCE
Sponsor Advantage Therapeutics GmbH
- Start (EU)
- Latest update
- Estimated end
- Not reported
Double-blind, randomized, placebo-controlled, phase III study comparing norursodeoxycholic acid capsules with placebo in the treatment of primary sclerosing cholangitis
Sponsor Dr. Falk Pharma GmbH
- Start (EU)
- Latest update
- Estimated end
IFCT-2502 LIMPID Phase II trial assessing 1st line and 2nd line treatment in patients with advanced Non-Small Cell Lung Cancer and Interstitial Lung Disease
Sponsor Intergroupe Francophone De Cancerologie Thoracique
- Start (EU)
- Not reported
- Latest update
- Estimated end
- Not reported
Long-Term Follow-up of Patients Treated with Miltenyi Cell and Gene Therapies
Sponsor Miltenyi Biomedicine GmbH
- Start (EU)
- Latest update
- Estimated end
- Not reported
A prospective, multi-centre, randomised, double-blind, placebo-controlled Phase III trial to investigate the efficacy and safety of lozenges with benzydamine hydrochloride and dichlorobenzyl alcohol in the symptomatic treatment of patients suffering from acute pharyngitis
Sponsor MEDICE Arzneimittel Puetter GmbH & Co. KG
- Start (EU)
- Not reported
- Latest update
- Estimated end
- Not reported
A phase I safety, dose finding and feasibility trial of MB-CART19.1 in patients with relapsed or refractory CD19 positive B cell malignancies
Sponsor Miltenyi Biomedicine GmbH
- Start (EU)
- Latest update
- Estimated end
- Not reported
CAR-T cells in systemic B cell mediated autoimmune disease - CASTLE
Sponsor Miltenyi Biomedicine GmbH
- Start (EU)
- Latest update
- Estimated end
- Not reported
Questions about this trial experience
What services are recorded for EvidentlQ Germany?
The 2026-10-09 snapshot links EvidentlQ Germany to 12 distinct CTIS trials. Recorded services include Electronic data capture, Interactive response technology (IRT), eCRF, EDC, SDTM, supportive statistics (Marvin tool used for building of eCRF), among 7 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for EvidentlQ Germany?
The most frequently recorded therapeutic areas are Cardiology. Recorded phases include Phase 3. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to EvidentlQ Germany conducted?
The linked trials record locations in 14 countries, including Germany, Austria, France, Italy, Netherlands. These are trial locations, not confirmed office locations or countries where EvidentlQ Germany delivered services.
What can this page tell me about EvidentlQ Germany's trial experience?
Browse 12 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under EvidentlQ Germany. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- EvidentlQ Germany GmbH